Featured Publications

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications
February 2025

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine
December 2023

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope
May 2023

Delivery Technology/Proprietary Delivery Device

Title	Disease Target	Product
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011	Delivery	CELLECTRA
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019	Delivery	CELLECTRA
Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation Molecular Therapy - Nucleic Acids — December 2023	Delivery	Vacuum-assisted Intradermal EP

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases